Correction to: Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting
verfasst von:
Peter Gæde, Pierre Johansen, Christian Klyver Tikkanen, Richard Fulton Pollock, Barnaby Hunt, Samuel Joseph Paul Malkin
In the original publication, Figs. 3 and 5 and the final sentence in the final paragraph of Results/Sensitivity Analyses were incorrectly published. The corrected statement and the figures are given below.
Additionally, the last few lines under the heading ‘Sensitivity Analyses’ should read as:
Anzeige
At a willingness-to-pay threshold of DKK 250,000 per QALY gained (a representative value based on GBP 20,000 in the UK), the probabilities of once-weekly semaglutide 0.5 mg and 1 mg being considered cost-effective were 72.4% and 96.5%, respectively, versus dulaglutide 1.5 mg (Fig. 5).
Fig. 3
Discounted direct costs over patient lifetimes in the primary analysis based on SUSTAIN 7. DKK 2017 Danish kroner
Fig. 5
Cost-effectiveness acceptability curve for the primary analysis versus dulaglutide, based on SUSTAIN 7. DKK 2017 Danish kroner, QALY quality-adjusted life year
×
×
Open Access
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Correction to: Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting
verfasst von
Peter Gæde Pierre Johansen Christian Klyver Tikkanen Richard Fulton Pollock Barnaby Hunt Samuel Joseph Paul Malkin
